Showing 9231-9240 of 19239 results for "".
- Revolutionizing Medication Adherence: MIT's Smart Ingestion Verification Pillhttps://reachmd.com/news/revolutionizing-medication-adherence-mits-smart-ingestion-verification-pill/2485299/MIT engineers have developed a smart ingestible pill that confirms medication ingestion for high-risk adherence monitoring, enabling near-real-time confirmation of swallowing events to guide timely interventions for patients at greatest risk from missed doses. The capsule contains a
- Reevaluating Anti-inflammatory Strategies in Trachomatous Trichiasis Surgery: Insights from the FLAME Trialhttps://reachmd.com/news/reevaluating-anti-inflammatory-strategies-in-trachomatous-trichiasis-surgery-insights-from-the-flame-trial/2485303/The FLAME trial found that topical fluorometholone does not reduce postoperative recurrence when used as an adjunct in trachomatous trichiasis surgery. Adding an ineffective anti-inflammatory diverts limited resources from proven surgical and programmatic interventions, prompting reevaluati
- The Cellular Impact of Weight Loss on Surgical Risk Managementhttps://reachmd.com/news/the-cellular-impact-of-weight-loss-on-surgical-risk-management/2485294/A University of Southern Denmark report shows that substantial surgical and lifestyle-induced weight loss shifts adipose tissue toward a lean cellular profile—important because adipose
- Addressing Adolescent Internet Addiction: The Roles of School Disconnectedness, Deprivation, and Resiliencehttps://reachmd.com/news/adolescent-internet-addiction-school-disconnectedness-deprivation-resilience/2485292/A large cross-sectional study of 2,485 adolescents found that school disconnectedness is associated with higher levels of problematic internet use. In this cross-sectional sample, school-c
- Inflammation and Clinical Impact in Long COVID: Emerging Insightshttps://reachmd.com/news/inflammation-and-clinical-impact-in-long-covid-emerging-insights/2485269/Emerging evidence links persistent inflammation and circulating micro‑clots to multisystem Long COVID morbidity, offering a plausible biological pa
- Immune-Targeting Therapy with Aldesleukin: A New Frontier in Post-MI Carehttps://reachmd.com/news/immune-targeting-therapy-with-aldesleukin-a-new-frontier-in-post-mi-care/2485273/IVORY trials show low-dose aldesleukin after acute myocardial infarction reduced vascular inflammation by an average of nearly 8% on imaging and blood markers — a targeted signal in a defined post‑MI subgroup.
- Immunonutrition in Ulcerative Colitis: A Preclinical Study of Arginine, Glutamine, and HMBhttps://reachmd.com/news/immunonutrition-in-ulcerative-colitis-a-preclinical-study-of-arginine-glutamine-and-hmb/2485271/In a single DSS-induced rat study, oral supplementation with arginine, glutamine, and HMB produced greater histopathological improvement and broader redu
- Enhancing Pediatric Emergency Triage and Analgesic Management: New Insights and Evolving Practiceshttps://reachmd.com/news/enhancing-pediatric-emergency-triage-and-analgesic-management-new-insights-and-evolving-practices/2485277/ICASS demonstrates superior sensitivity for identifying children likely to require pediatric trauma-center resources, supporting a practice-ready shift in how undertriage
- Emerging Innovations in Cellular and Antibody Immunotherapies: Cancer Treatment Redefinedhttps://reachmd.com/news/emerging-innovations-in-cellular-and-antibody-immunotherapies-cancer-treatment-redefined/2485282/Bispecific CAR T cells targeting BCMA and BAFF‑R offer a two‑pronged cytotoxic strategy that may prevent relapse from single‑antigen loss in relapsed/refractory multiple myeloma—an approach with immediate translational relevance where single‑antigen therapies have failed.</
- Analysis: Ustekinumab, IL-23 Inhibitors Show Higher Drug Survival in Psoriasishttps://reachmd.com/news/analysis-ustekinumab-il-23-inhibitors-show-higher-drug-survival-in-psoriasis/2485295/A new Danish cohort study using data from the DERMBIO registry suggests ustekinumab was linked with the best 5-year survival of comparators in bionaive patients with psoriasis. The analysis included a total of 7,193 treatment